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Figure 1 Two small non-coding RNAs (miR-9 and miR-10b) and the complex 
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Metastasis accounts for more than 
90% of cancer patients’ mortality. The 
metastatic process involves multiple 
steps [1]. Initially, cancer cells from the 
primary tumor invade adjacent stroma. 
To acquire this capacity, cells undergo a 
process called epithelial-mesenchymal 
transition (EMT), in which cells in re-
sponse to signals from the surrounding 
stroma, undergo a switch between cell 
phenotypes and acquire mesenchymal 
properties and show reduced intercel-
lular adhesion, allowing cells to be-
come motile. Then cells enter systemic 
circulation, either through the blood or 
lymph, and finally extravasate into the 
parenchyma of distant tissues, where 
they form micrometastasis and prolifer-
ate to form secondary tumors [2].
MicroRNAs (miRNAs) are a class of 
non-coding RNAs with approximately 
22 nt length that regulate gene expres-
sion post-transcriptionally by binding 
to 3′ untranslated region (UTR), coding 
sequence or 5′ UTR of target messenger 
RNAs (mRNAs), leading to inhibition 
of translation or mRNA degradation 
[3]. Tumors present aberrant expression 
of miRNAs patterns. miRNAs have 
been described as regulators of several 
biological processes such as apoptosis, 
proliferation, differentiation, and more 
recently, metastasis [4]. miRNAs can 
function either as suppressors or pro-
moters of metastasis according to their 
mRNA targets [1, 2]. Elucidation of the 
role of miRNAs in metastasis can lead 
to a better understanding of this process 
and consequently lead to new treatments 
for patients with late-stage tumors.
In 2007, Ma and coworkers from 
Weinberg’s group reported the first 
study about the role of miRNAs in tumor 
metastasis [5]. The authors identified 
three miRNAs, namely miR-155, miR-9 
and miR-10b, as being upregulated in 
breast cancer cell lines and showed that 
miRNA-10b, by targeting HOXD10a, 
induce the pro-metastatic gene RHOC 
and consequently contribute to me-
tastasis [5]. In a recent publication in 
Nat Cell Biol [6], Ma and colleagues 
elegantly show the involvement of 
miR-9 in the metastasis-regulating sig-
naling network (Figure 1). A common 
approach to identify miRNA targets is 
the use of computational algorithms 
whereby the authors identify and further 
confirm by luciferase assay and western 
blot that the cell-cell adhesion receptor 
E-cadherin (encoded by CDH1) is a di-
rect target of miR-9. This miRNA binds 
to CDH1 3′UTR region as a decrease in 
luciferase activity was detected in cells 
co-transfected with miR-9 and CDH1 
3′UTR reporter gene. To further confirm 
this result, the authors show that co-
transfection of miR-9 and CDH1 3′UTR 
reporter gene containing a mutation in 
the seed-target region do not cause a 
decrease in luciferase activity [6].
This finding is important because, 
as it has long been recognized, loss of 
E-cadherin expression is one of the hall-
marks of EMT process [7]. E-cadherin is 
a transmembrane protein whose primary 
function is to mediate cell adhesion. 
The cytoplasmic tail of E-cadherin as-
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sociates with several proteins including 
β-catenin. Besides its involvement in 
cell adhesion, β-catenin is an essential 
effector of the Wnt signaling pathway 
which is frequently upregulated in tu-
mors [8]. Specifically, β-catenin forms 
a transcription factor complex with 
TCF to regulate gene expression. When 
β-catenin escapes degradation, it accu-
mulates in the cytosol and can enter the 
nucleus where it will act as a transcrip-
tional co-regulator [7, 8]. miR-9 upregu-
lation in breast cancer cells suppresses 
E-cadherin that consequently loses its 
capacity to sequester β-catenin and 
potentiates the Wnt signaling. In fact, 
the authors show that miR-9 expression 
increases β-catenin activity in cell lines 
with a basal E-cadherin expression. In 
vivo, miR-9 overexpressing tumor xe-
nografts develop more micrometastasis 
than tumor xenografts without miR-9 
overexpression. In addition, in vivo, 
inhibition of miR-9 can decrease metas-
tasis formation [6]. Silencing of miR-9 
and modulating E-cadherin expression 
may represent a new therapeutic ap-
proach in advanced breast cancers to 
prevent metastasis formation.
Study by Ma et al. is exciting because 
the authors demonstrate the contribu-
tion of miR-9 not only for EMT but 
also for induction of angiogenesis that 
is essential for metastasis to develop. 
VEGFA is a key pro-angiogenic protein 
and a target of β-catenin [9]. Ma et al. 
show that miR-9 overexpression up-
regulates VEGFA and that it correlates 
with E-cadherin expression. In vivo, the 
same result is obtained: VEGFA plasma 
levels in miR-9-overexpressing tumor 
xenografts are higher than in controls 
indicating the role of miR-9 in tumor 
angiogenesis. However, by itself E-
cadherin and β-catenin do not induce 
VEGFA upregulation [6]. Therefore, 
other miR-9 targets have to be consid-
ered. In future studies it will be interest-
ing to answer the question what other 
proteins/pathways may mediate VEGFA 
upregulation via miR-9 overexpression. 
Finally, Ma et al. explore upstream 
pathway of miR-9 expression regula-
tion and find out its activation by MYC/
MYCN. The authors correlate miR-9 
upregulation with MYC amplification 
in neuroblastomas tumor samples and 
also with metastatic breast tumors [6]. 
However, the number of breast cancer 
samples used in the study is reduced and 
so it remains to be determined if miR-9 
can be used as a prognostic marker since 
large breast cancer association studies 
are needed for this. In conclusion, this 
study convincingly identifies a new 
player in both EMT and angiogenic 
processes – miR-9, and opens intriguing 
new avenues of diagnostic and therapy: 
Do miR-9 levels in tumors and/or 
plasma of breast cancer patients predict 
metastasis? Should anti-miR-9 (and 
anti-miR-10b) be used for metastases 
prophylaxis in cancer patients?
Currently the role of miRNAs as one 
of key regulators of the metastatic pro-
cess is starting to be clarified. Similar 
to miRNAs, other non-coding RNAs 
(ncRNAs) were shown to be deregu-
lated in tumors [10]. In the future, it 
will be interesting to address the role of 
other ncRNAs in the complex molecular 
puzzle of metastasis.
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